换一批Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
第一作者：
Qing,Huang
第一单位：
Janssen Scientific Affairs, LLC, Horsham, PA, USA.
作者：
医学主题词
腺嘌呤(Adenine);老年人(Aged);费用节省(Cost Savings);女(雌)性(Female);卫生保健费用(Health Care Costs);人类(Humans);免疫疗法(Immunotherapy);白血病, 淋巴细胞, 慢性, B细胞(Leukemia, Lymphocytic, Chronic, B-Cell);男(雄)性(Male);Medicare(Medicare);病人接受卫生保健的程度(Patient Acceptance of Health Care);哌啶类(Piperidines);回顾性研究(Retrospective Studies);美国(United States)
DOI
10.1080/03007995.2020.1835851
PMID
33044848
发布时间
2021-06-22
- 浏览1
Current medical research and opinion
2009-2018页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
